Table 1.
Urine output, free water clearance (CH2O), urinary AQP2 excretion per minute (u-AQP2), urinary sodium excretion (u-Na), and urinary potassium excretion (u-K) during 24-h urine collection in a randomised, placebo-controlled, double-blind, crossover study of 18 ADPKD patients
| Before each examination day | p (paired t-test) | ||
|---|---|---|---|
| Placebo | Tolvaptan 60 mg | ||
| Urine Output (ml/24 h) | 2504 ± 518 | 2446 ± 615 | 0.57 |
| CH2O (ml/min) | −0.22 ± 0.55 | −0.19 ± 0.57 | 0.72 |
| u-AQP2 (ng/min) | 1.10 ± 0.26 | 1.09 ± 0.28 | 0.88 |
| u-Na (mmol/24 h) | 117 ± 34 | 111 ± 28 | 0.46 |
| u-K (mmol/24 h) | 66 ± 17 | 65 ± 18 | 0.77 |
Values are means with ± SD. Paired t-test was used for comparison between groups